Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?

  title={Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?},
  author={C. Cleeland and G. Bennett and R. Dantzer and P. Dougherty and A. Dunn and C. Meyers and A. Miller and R. Payne and J. Reuben and X. Wang and Bang-Ning Lee},
  • C. Cleeland, G. Bennett, +8 authors Bang-Ning Lee
  • Published 2003
  • Medicine
  • Cancer
  • Cancers and cancer treatments produce multiple symptoms that collectively cause a symptom burden for patients. These symptoms include pain, wasting, fatigue, cognitive impairment, anxiety, and depression, many of which co‐occur. There is growing recognition that at least some of these symptoms may share common biologic mechanisms. 
    463 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of this study among breast cancer survivors is three-fold: (i) to evaluate the efficacy of the MBSR(BC) program in improving psychological and physical symptoms, quality of… Expand
    ConditionsBreast Cancer
    Chemotherapy‐Induced Neuropathic Pain and Its Relation to Cluster Symptoms in Breast Cancer Patients Treated with Paclitaxel
    • 31
    Breast Cancer and Fatigue.
    • 69
    Symptoms: Fatigue and Cognitive Dysfunction.
    • 16
    • PDF
    Expectations of Pain and Accompanying Symptoms during Cancer Treatment
    • 2
    Associations Between Cytokine Levels and Long-Term Symptom Development in Head and Neck Cancer Patients
    • B. Schultze
    • Medicine
    • Journal of the advanced practitioner in oncology
    • 2019


    The role of cytokines in cancer‐related fatigue
    • 229
    Cancer-related symptoms.
    • 123
    The biologic basis of fatigue
    • 132
    Assessing symptom distress in cancer patients
    • 542
    Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.
    • 186
    Chemotherapy-induced peripheral neuropathy.
    • 85
    Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
    • 241